Look back at pharma news in the week to August 21, 2020
By Barbara Obstoj-Cardwell. Editor
Last week’s notable news included French pharma major Sanofi last Monday announcing it was buying US firm Principia Biopharma for $3.68 billion, along with its BTK inhibitors SAR442168 for multiple sclerosis and rilzabrutinib for autoimmune diseases. Also, Johnson & Johnson announced its biggest acquisition since that of Actelion for $30 billion in 2017, when it agreed to buy Momenta Pharmaceuticals for $6.5 billion, taking in the autoimmune diseases candidate nipocalimab. Israel-based Teva Pharmaceutical Industries took a hit last Tuesday when the US Department of Justice sued the company over kickbacks relating to its top-selling multiple sclerosis drug Copaxone. And last Wednesday, US biotech Regeneron Pharmaceuticals enlisted help from Swiss giant Roche to develop and manufacture its REGN-COV2, an antibody cocktail for the treatment of COVID-19.
Sanofi pays up for Principia
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze